Metallothioneins (MT) are low molecular weight, cysteine-rich proteins maintaining metal ions homeostasis. They play a role in carcinogenesis and may also cause chemoresistance. The aim of the study was to explore the importance of MT serum levels in children suffering from malignant tumours. This prospective study involves examination of 865 samples from 172 patients with malignant tumours treated from 2008 to 2011 at University Hospital Motol. MT serum levels were determined using differential pulse voltammetry-Brdicka reaction. Mean MT level was 2.7 ± 0.5 μM. There was no statistically significant difference between MT levels in different tumours. We also did not find any correlation between MT levels and response to therapy or clinical stages. However, we found a positive correlation between MT levels and age (p = 0.009) and a negative correlation with absolute lymphocyte number (p = 0.001). The fact that patients who had early disease recurrence had lower MT levels during the treatment (complete remission 2.67 vs. recurring 2.34, p = 0.001) seems to be important for clinical practice. Accordingly we believe that there is benefit in further studies of serum MT levels in tumours.

Department of Paediatric Haematology and Oncology 2nd Medical Faculty and University Hospital Motol 5 Uvalu 84 Prague CZ 150 06 Czech Republic

Zobrazit více v PubMed

Eckschlager T., Adam V., Hrabeta J., Figova K., Kizek R. Metallothioneins and cancer. Curr. Protein Pept. Sci. 2009;10:360–375. PubMed

Simpkins C.O. Metallothionein in human disease. Cell. Mol. Biol. 2000;46:465–488. PubMed

Theocharis S.E., Margeli A.P., Klijanienko J.T., Kouraklis G.P. Metallothionein expression in human neoplasia. Histopathology. 2004;45:103–118. PubMed

Choudhuri S., Kramer K.K., Berman N.E., Dalton T.P., Andrews G.K., Klaassen C.D. Constitutive expression of metallothionein genes in mouse brain. Toxicol. Appl. Pharmacol. 1995;131:144–154. PubMed

Faller P. Neuronal growth-inhibitory factor (metallothionein-3): Reactivity and structure of metal-thiolate clusters. FEBS J. 2010;277:2921–2930. PubMed

Namdarghanbari M., Wobig W., Krezoski S., Tabatabai N.M., Petering D.H. Mammalian metallothionein in toxicology, cancer, and cancer chemotherapy. J. Biol. Inorg. Chem. 2011;16:1087–1101. PubMed

Sutherland D.E.K., Stillman M.J. The “Magic numbers” of metallothionein. Metallomics. 2011;3:444–463. PubMed

Suemori S., Shimazawa M., Kawase K., Satoh M., Nagase H., Yamamoto T., Hara H. Metallothionein, an endogenous antioxidant, protects against retinal neuron damage in mice. Invest. Ophthalmol. Vis. Sci. 2006;47:3975–3982. PubMed

Michalska A.E., Choo K.H. Targeting and germ-line transmission of a null mutation at the metallothionein i and ii loci in mouse. Proc. Natl. Acad. Sci. USA. 1993;90:8088–8092. PubMed PMC

DeLisle R.C., Sarras M.P., Hidalgo J., Andrews G.K. Metallothionein is a component of exocrine pancreas secretion: Implications for zinc homeostasis. Am. J. Physiol. Cell. Physiol. 1996;271:C1103–C1110. PubMed

Trayhurn P., Duncan J.S., Wood A.M., Beattie J.H. Metallothionein gene expression and secretion in white adipose tissue. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2000;279:R2329–R2335. PubMed

Evering W., Haywood S., Bremner I., Wood A.M., Trafford J. The protective role of metallothionein in copper-overload. 2. Transport and excretion of immunoreactive mt-1 in blood, bile and urine of copper-loaded rats. Chem. Biol. Interact. 1991;78:297–305. PubMed

Maret W. Metalloproteomics, metalloproteomes, and the annotation of metalloproteins. Metallomics. 2010;2:117–125. PubMed

Suzuki T., Suzuki K., Nakajima K., Otaki N., Yamanaka H. Metallothionein in human seminal plasma. Int. J. Urol. 1994;1:345–348. PubMed

Penkowa M. Metallothionein i+ii expression and roles during neuropathology in the cns. Dan. Med. Bull. 2006;53:105–121. PubMed

Penkowa M., Florit S., Giralt M., Quintana A., Molinero A., Carrasco J., Hidalgo J. Metallothionein reduces central nervous system inflammation, neuro degeneration, and cell death following kainic acid-induced epileptic seizures. J. Neurosci. Res. 2005;79:522–534. PubMed

Babula P., Masarik M., Adam V., Eckschlager T., Stiborova M., Trnkova L., Skutkova H., Provaznik I., Hubalek J., Kizek R. Mammalian metallothioneins: Properties and functions. Metallomics. 2012;4:739–750. PubMed

Takahashi S. Molecular functions of metallothionein and its role in hematological malignancies. J. Hematol. Oncol. 2012;5:1–8. PubMed PMC

Choi C.H., Cha Y.J., An C.S., Kim K.J., Kim K.C., Moon S.P., Lee Z.H., Min Y.D. Molecular mechanisms of heptaplatin effective against cisplatin-resistant cancer cell lines: Less involvement of metallothionein. Cancer Cell. Int. 2004;4:1–12. PubMed PMC

Hagrman D., Goodisman J., Dabrowiak J.C., Souid A.K. Kinetic study on the reaction of cisplatin with metallothionein. Drug Metab. Dispos. 2003;31:916–923. PubMed

Takaishi M., Sawada M., Shimada A., Suzuki J.S., Satoh M., Nagase H. Protective role of metallothionein in benzo a pyrene-induced DNA damage. J. Toxicol. Sci. 2009;34:449–458. PubMed

Bacolod M.D., Fehdrau R., Johnson S.P., Bullock N.S., Bigner D.D., Colvin M., Friedman H.S. Bcnu-sequestration by metallothioneins may contribute to resistance in a medulloblastoma cell line. Cancer Chemother. Pharmacol. 2009;63:753–758. PubMed PMC

Krizkova S., Fabrik I., Adam V., Hrabeta J., Eckschlager T., Kizek R. Metallothionein—A promising tool for cancer diagnostics. Bratisl. Med. J. Bratisl. Lek. Listy. 2009;110:93–97. PubMed

Samson S.L., Gedamu L. Molecular analyses of metallothionein gene regulation. Prog. Nucleic Acid Res. Mol. Biol. 1998;59:257–288. PubMed

Hynek D., Krizkova S., Krejcova L., Gumulec J., Ryvolova M., Cernei N., Masarik M., Adam V., Trnkova L., Stiborova M., et al. Femtogram electroanalytical detection of prostatic specific antigen by brdicka reaction. Int. J. Electrochem. Sci. 2012;7:1749–1766.

Milnerowicz H., Bizon A. Determination of metallothionein in biological fluids using enzyme-linked immunoassay with commercial antibody. Acta Biochim. Pol. 2010;57:99–104. PubMed

Singh V.K., Hanson J. Assessment of metallothionein and antibodies to metallothionein in normal and autistic children having exposure to vaccine-derived thimerosal. Pediatr. Allergy Immunol. 2006;17:291–296. PubMed

Kruseova J. University Hospital Motol; Prague, Czech Republic: 2013. Unpublished work.

Ostrakhovitch E.A., Olsson P.E., Jiang S., Cherian M.G. Interaction of metallothionein with tumor suppressor p53 protein. FEBS Lett. 2006;580:1235–1238. PubMed

Gibson R.S., Hess S.Y., Hotz C., Brown K.H. Indicators of zinc status at the population level: A review of the evidence. Br. J. Nutr. 2008;99:S14–S23. PubMed

Dutsch-Wicherek M., Sikora J., Tomaszewska R. The possible biological role of metallothionein in apoptosis. Front. Biosci. 2008;13:4029–4038. PubMed

Hinkel A., Schmidtchen S., Palisaar R.J., Noldus J., Pannek J. Identification of bladder cancer patients at risk for recurrence or progression: An immunohistochemical study based on the expression of metallothionein. J. Toxicol. Env. Health Part A. 2008;71:954–959. PubMed

Cardoso S.V., Silveira J.B., Machado V.D., De-Paula A.M.B., Loyola A.M., de Aguiar M.C.F. Expression of metallothionein and p53 antigens are correlated in oral squamous cell carcinoma. Anticancer Res. 2009;29:1189–1193. PubMed

Lara-Bohorquez C., Gonzalez-Campora R., Mendoza-Garcia E., Rios-Martin J.J., Pareja-Megia M.J., Lopez-Beltran A. Tp53, bcl-2. P21(waf1/cip1) and metallothionein as markers of differentiation, response to treatment and prognosis in neuroblastic tumors. Anal. Quant. Cytol. Histol. 2008;30:105–112. PubMed

Peyre M., Commo F., Dantas-Barbosa C., Andreiuolo F., Puget S., Lacroix L., Drusch F., Scott V., Varlet P., Mauguen A., et al. Portrait of ependymoma recurrence in children: Biomarkers of tumor progression identified by dual-color microarray-based gene expression analysis. PLoS One. 2010;5:e12932. PubMed PMC

Endo-Munoz L., Cumming A., Sommerville S., Dickinson I., Saunders N.A. Osteosarcoma is characterised by reduced expression of markers of osteoclastogenesis and antigen presentation compared with normal bone. Br. J. Cancer. 2010;103:73–81. PubMed PMC

Sauerbrey A., Zintl F., Volm M. Expression of metallothionein in initial and relapsed childhood acute lymphoblastic-leukemia. Ann. Hematol. 1994;69:111–115. PubMed

Weinlich G., Eisendle K., Hassler E., Baltaci M., Fritsch P.O., Zelger B. Metallothionein— Overexpression as a highly significant prognostic factor in melanoma: A prospective study on 1270 patients. Br. J. Cancer. 2006;94:835–841. PubMed PMC

Weinlich G. Metallothionein-overexpression as a prognostic marker in melanoma. G. Ital. Dermatol. Venereol. 2009;144:27–38. PubMed

Schmitz K.J., Muller C.I., Reis H., Alakus H., Winde G., Baba H.A., Wohlschlaeger J., Jasani B., Fandrey J., Schmid K.W. Combined analysis of hypoxia-inducible factor 1 alpha and metallothionein indicates an aggressive subtype of colorectal carcinoma. Int. J. Colorectal Dis. 2009;24:1287–1296. PubMed

Pontes H.A.R., Xavier F.C.D., da Silva T.S.P., Fonseca F.P., Paiva H.B., Pontes F.S.C., Pinto D.D. Metallothionein and p-akt proteins in oral dysplasia and in oral squamous cell carcinoma: An immunohistochemical study. J. Oral Pathol. Med. 2009;38:644–650. PubMed

Yap X.L., Tan H.Y., Huang J.X., Lai Y.Y., Yip G.W.C., Tan P.H., Bay B.H. Over-expression of metallothionein predicts chemoresistance in breast cancer. J. Pathol. 2009;217:563–570. PubMed

Grabellus F., Sheu S.Y., Totsch M., Lehmann N., Kaiser G.M., Jasani B., Taeger G., Schmid K.W. Overexpression of the drug resistance-associated protein metallothionein does not correlate with response of sarcomas to isolated limb perfusion treatment. J. Surg. Oncol. 2010;101:465–470. PubMed

Formigare A., Irato P., Santon A. Zinc, antioxidant systems and metallothionein in metal mediated-apoptosis: Biochemical and cytochemical aspects. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 2007;146:443–459. PubMed

Hiura T., Khalid H., Yamashita H., Tokunaga Y., Yasunaga A., Shibata S. Immunohistochemical analysis of metallothionein in astrocytic tumors in relation to tumor grade, proliferative potential, and survival. Cancer. 1998;83:2361–2369. PubMed

Szelachowska J., Dziegiel P., Jelen-Krzeszewska J., Jelen M., Tarkowski R., Spytkowska B., Matkowski R., Kornafel J. Correlation of metallothionein expression with clinical progression of cancer in the oral cavity. Anticancer Res. 2009;29:589–595. PubMed

Swierzcek S., Abuknesha R.A., Chivers I., Baranovska I., Cunningham P., Price R.G. Enzyme-immunoassay for the determination of metallothionein in human urine: Application to environmental monitoring. Biomarkers. 2004;9:331–340. PubMed

Gumulec J., Masarik M., Krizkova S., Hlavna M., Babula P., Hrabec R., Rovny A., Masarikova M., Sochor J., Adam V., et al. Evaluation of alpha-methylacyl-CoA racemase, metallothionein and prostate specific antigen as prostate cancer prognostic markers. Neoplasma. 2012;59:191–200. PubMed

Krejcova L., Fabrik I., Hynek D., Krizkova S., Gumulec J., Ryvolova M., Adam V., Babula P., Trnkova L., Stiborova M., et al. Metallothionein electrochemically determined using brdicka reaction as a promising blood marker of head and neck malignant tumours. Int. J. Electrochem. Sci. 2012;7:1767–1784.

Sochor J., Hynek D., Krejcova L., Fabrik I., Krizkova S., Gumulec J., Adam V., Babula P., Trnkova L., Stiborova M., et al. Study of metallothionein role in spinocellular carcinoma tissues of head and neck tumours using brdicka reaction. Int. J. Electrochem. Sci. 2012;7:2136–2152.

Nakayama A., Fukuda H., Ebara M., Hamasaki H., Nakajima K., Sakurai H. A new diagnostic method for chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma based on serum metallothionein, copper, and zinc levels. Biol. Pharmacol. Bull. 2002;25:426–431. PubMed

Rickert C.H., Paulus W. Prognosis-related histomorphological and immunohistochemical markers in central nervous system tumors of childhood and adolescence. Acta Neuropathol. 2005;109:69–92. PubMed

Natale J.E., Knight J.B., Cheng Y., Rome J.E., Gallo V. Metallothionein i and ii mitigate age-dependent secondary brain injury. J. Neurosci. Res. 2004;78:303–314. PubMed

Bell S.G., Vallee B.L. The metallothionein/thionein system: An oxidoreductive metabolic zinc link. ChemBioChem. 2009;10:55–62. PubMed

Tsukahara H. Biomarkers for oxidative stress: Clinical application in pediatric medicine. Curr. Med. Chem. 2007;14:339–351. PubMed

Arvin L.R.a.A. Chemotherapy-induced immunosupression. Environ. Health Perspect. 1982;43:4. PubMed PMC

Surowiak P., Materna V., Maciejczyk A., Pudelko M., Markwitz E., Spaczynski M., Dietel M., Zabel M., Lage H. Nuclear metallothionein expression correlates with cisplatin resistance of ovarian cancer cells and poor clinical outcome. Virchows. Arch. 2007;450:279–285. PubMed

Endo T., Yoshikawa M., Ebara M., Kato K., Sunaga M., Fukuda H., Hayasaka A., Kondo F., Sugiura N., Saisho H. Immunohistochemical metallothionein expression in hepatocellular carcinoma: Relation to tumor progression and chemoresistance to platinum agents. J. Gastroenterol. 2004;39:1196–1201. PubMed

Suganuma K., Kubota T., Saikawa Y., Abe S., Otani Y., Furukawa T., Kumai K., Hasegawa H., Watanabe M., Kitajima M., et al. Possible chemoresistance-related genes for gastric cancer detected by cdna microarray. Cancer Sci. 2003;94:355–359. PubMed PMC

Bacolod M.D., Johnson S.P., Ali-Osman F., Modrich P., Bullock N.S., Colvin O.M., Bigner D.D., Friedman H.S. Mechanisms of resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea in human medulloblastoma and rhabdomyosarcoma. Mol. Cancer Ther. 2002;1:727–736. PubMed

Sunada F., Itabashi M., Ohkura H., Okumura T. P53 negativity, cdc25b positivity, and metallothionein negativity are predictors of a response of esophageal squamous cell carcinoma to chemoradiotherapy. World J. Gastroenterol. 2005;11:5696–5700. PubMed PMC

Hishikawa Y., Abe S., Kinugasa S., Yoshimura H., Monden N., Igarashi M., Tachibana M., Nagasue N. Overexpression of metallothionein correlates with chemoresistance to cisplatin and prognosis in esophageal cancer. Oncology. 1997;54:342–347. PubMed

Malavolta M., Cipriano C., Costarelli L., Giacconi R., Tesei S., Muti E., Piacenza F., Pierpaoli S., Larbi A., Pawelec G., et al. Metallothionein downregulation in very old age: A phenomenon associated with cellular senescence? Rejuv. Res. 2008;11:455–459. PubMed

Bauerly K.A., Kelleher S.L., Lonnerdal B. Effects of copper supplementation on copper absorption, tissue distribution, and copper transporter expression in an infant rat model. Am. J. Physiol. Gastrointest. Liver Physiol. 2005;288:G1007–1014. PubMed

Wong H.R., Shanley T.P., Sakthivel B., Cvijanovich N., Lin R., Allen G.L., Thomas N.J., Doctor A., Kalyanaraman M., Tofil N.M., et al. Genome-level expression profiles in pediatric septic shock indicate a role for altered zinc homeostasis in poor outcome. Physiol. Genomics. 2007;30:146–155. PubMed PMC

Cvijanovich N.Z., King J.C., Flori H.R., Gildengorin G., Wong H.R. Zinc homeostasis in pediatric critical illness. Pediatr. Crit. Care Med. 2009;10:29–34. PubMed

Erk M., Ivankovic D., Raspor B., Pavicic J. Evaluation of different purification procedures for the electrochemical quantification of mussel metallothioneins. Talanta. 2002;57:1211–1218. PubMed

Ryvolova M., Krizkova S., Adam V., Beklova M., Trnkova L., Hubalek J., Kizek R. Analytical methods for metallothionein detection. Curr. Anal. Chem. 2011;7:243–261.

Ryvolova M., Adam V., Kizek R. Analysis of metallothionein by capillary electrophoresis. J. Chromatogr. A. 2012;1226:31–42. PubMed

Fabrik I., Krizkova S., Huska D., Adam V., Hubalek J., Trnkova L., Eckschlager T., Kukacka J., Prusa R., Kizek R. Employment of electrochemical techniques for metallothionein determination in tumor cell lines and patients with a tumor disease. Electroanalysis. 2008;20:1521–1532.

Adam V., Baloun J., Fabrik I., Trnkova L., Kizek R. An electrochemical detection of metallothioneins at the zeptomole level in nanolitre volumes. Sensors. 2008;8:2293–2305. PubMed PMC

Raspor B. Elucidation of the mechanism of the brdicka reaction. J. Electroanal. Chem. 2001;503:159–162.

Adam V., Petrlova J., Wang J., Eckschlager T., Trnkova L., Kizek R. Zeptomole electrochemical detection of metallothioneins. PLoS One. 2010;5:e11441. PubMed PMC

Krizkova S., Adam V., Eckschlager T., Kizek R. Using of chicken antibodies for metallothionein detection in human blood serum and cadmium-treated tumour cell lines after dot- and electroblotting. Electrophoresis. 2009;30:3726–3735. PubMed

Krizikova S.F.I, Adam V., Kukacka J., Prusa R., Chavis G.J., Trnkova L., Strnadel J., Horak V., Kizek R. Utilizing of adsorptive transfer stripping tecchnique brdicka reaction for determination of metallothioneins level in melanoma cells, blood serum and tissues. Sensor. 2008;8:3106–3122. PubMed PMC

Zinc and zinc-containing biomolecules in childhood brain tumors